This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.
In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.
In your application messsage, please share your background and what you can contribute to the group.
Company Overview and News
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
JPXGY MZHOF C.WSA DB OSCUF C C.PRL C.PRJ C.PRK C.PRG C.PRC FIG C.WS.B C.PRPCL CGBBW C.WS.A C.PRP C.PRU 8697 8411 MFG C.PRS
NEW YORK, July 16, 2018 (GLOBE NEWSWIRE) -- Fortress Transportation and Infrastructure Investors LLC (NYSE:FTAI) today announced that Joe Adams, FTAI Chief Executive Officer, will present at the Jefferies 2018 Global Industrials Conference at 1:40PM (ET) on Thursday, August 9, 2018 at The InterContinental New York Barclay.
NEW YORK, July 05, 2018 (GLOBE NEWSWIRE) -- Fortress Transportation and Infrastructure Investors LLC (NYSE:FTAI) (the "Company") plans to announce its financial results for the second quarter 2018 after the closing of the New York Stock Exchange on Thursday, August 2, 2018. A copy of the press release and an earnings supplement will be posted to the Investor Relations section of the Company's website, www.
FIG FTAI DTK
(June 21): Guggenheim Partners is exploring the sale of a stake in its US$250 billion asset-management unit overseen by Scott Minerd, according to people familiar with the matter.
DB MET MS.PRE MS.PRF MS.PRG MS.PRA MET.PRA FIG MET MET.PRE MS.PRI MS.PRK MS IVZ
With the criminal fraud charges leveled at Theranos founder Elizabeth Holmes and former company president Ramesh “Sunny” Balwani last Friday afternoon, David Taylor, the company’s General Counsel, has taken over as chief executive officer of the beleaguered company.
TOKYO (June 20): Masayoshi Son is elevating two SoftBank Group Corp executives and one outsider to his inner circle, appointments that become official on Wednesday.
DB BNPQY GS.PRB GS.PRA SFTBF FIG GS GLSSP AAPL JEF SFTBY JBK TMUSP GSC GS.PRICL TMUS TFG BNPQF GSJ GS.PRJ BNPZY GS.PRI S GS.PRD GS.PRC 9984 GJS GS.PRN GS.PRK
MILAN (June 19): Italy's doBank plans to take on the management of a further 15 billion euros (US$17 billion) in bad loans by 2020, as it strives to preserve its sector leadership amid rising competition.
REDWOOD SHORES, Calif., June 19, 2018 (GLOBE NEWSWIRE) -- iPass Inc. (NASDAQ:IPAS), a leading provider of global mobile connectivity, today announced that it has finalized a senior secured credit facility of up to $20 million from affiliates of funds managed by affiliates of Fortress Investment Group LLC . This facility is secured by all of iPass’ assets, including its patent portfolio. B. Riley FBR, Inc.
FIG IPAS RILY UNTD
MILAN (Reuters) - Italy’s doBank (DOB.MI) plans to take on the management of a further 15 billion euros ($17 billion) in bad loans by 2020 as it strives to preserve its sector leadership amid rising competition.
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
Silicon Investor Message Boards
This table lists all message boards related to FIG / Fortress Investment Group LLC on message board site Silicon Investor.
as of ET